Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.33 |
| ▸ | FEN1 | P39748 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554384 | 0.79 | CNR2 (0.39) | CNR2 | |
| SCHEMBL3554209 | 0.79 | PARG (0.45) | PARGTP53L3MBTL1ALOX5APFEN1 | |
| SCHEMBL3554212 | 0.78 | PARG (0.41) | PARGTP53L3MBTL1ALOX5APFEN1 | |
| SCHEMBL3558367 | 0.77 | KIF11 (0.39) | ALOX5APFEN1LMNAKIF11 | |
| SCHEMBL23938540 | 0.73 | CYP3A4 (0.37) | — | |
| SCHEMBL9797321 | 0.69 | CES2 (0.37) | ALDH1A1 | |
| SCHEMBL14854407 | 0.66 | ALOX5AP (0.42) | IDH1L3MBTL1ALOX5APFEN1ALDH1A1 | |
| SCHEMBL28231674 | 0.66 | SLC6A4 (0.40) | L3MBTL1ALDH1A1MCL1 | |
| SCHEMBL1986356 | 0.66 | GABRA1 (0.46) | ALDH1A1CNR2 | |
| SCHEMBL20751779 | 0.66 | PDE2A (0.38) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | PARG 1052/4885TP53 4817/4885IDH1 4869/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | PARG 934/4885TP53 4825/4885IDH1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.